In the study by Han and Roman, PPARγ ligands inhibited human NSCLC growth by decreasing the expression of EP2 receptors through Erk signaling and both PPARγ-dependent and -independent pathways. The gene discussed is PPARG; the disease is non-small cell lung carcinoma.